Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q3 2024 earnings summary

Executive summary

• Achieved a turnaround in free cash generation in Q3 2024, with free cash flow of R$20.3 million, reversing prior quarters of cash consumption, driven by improved collections and disciplined capex.

• Gross revenue reached R$1.7 billion to R$1,745.1 million, up 12.9% year-over-year; net revenue was R$1,634.9 million, up 16.7% year-over-year, driven by higher treatment volumes and ramp-up of cancer centers.

• Procedures grew 7.9% year-over-year in Q3 2024, with average ticket up 4.9%.

• Net income ex-LTIP was R$8.9 million, but net income attributable to controlling shareholders was R$-15.9 million, reflecting higher financial expenses and tax effects.

• A R$1.5 billion capital increase in July 2024 strengthened the balance sheet and reduced financial expenses.

Financial highlights

• EBITDA for Q3 2024 was R$271.5 million (16.6% margin), with adjusted EBITDA at R$309.0 million (18.9% margin); gross profit was R$551 million, gross margin at 33.7%.

• Cash receipts improved to 92.4% of net revenue in Q3 2024, up from 79.0% in 4Q23.

• PCLD (provision for doubtful accounts) dropped to 0.5% of gross revenue, the lowest in two years.

• Free cash flow for Q3 was R$207.3 million, driven by improved receipts and working capital.

• Cash flow from operations was R$198.3 million, a significant improvement from the previous quarter.

Outlook and guidance

• Year-end 2024 leverage guidance reaffirmed at 2.7x net debt/EBITDA, supported by organic cash generation and capital increase.

• Management expects PCLD to normalize to historical levels (2%-2.5%) after a temporary low of 0.5% in Q3.

• Focus remains on cash generation and operational efficiency, even if it results in temporarily lower margins or slower growth.

• Continued growth in treatment volumes and operational efficiency gains expected from recent reorganizations.